We have downgraded our rating on Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) from Outperform to Neutral with a target price of $11.00 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases.
Alnylam’s core product strategy, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards